More than 200 interstitial lung diseases (ILD) — from rare to relatively common – are now recognized in the United States, with most forms characterized by inflammation or fibrosis within the interstitial space. While the past several years have brought significant advances in management, the timely implementation of contemporary diagnostic and therapeutic pathways has been inconsistent by clinicians, in part due to a lack of coordinated, multidisciplinary care. Moreover, disparities in screening and treatment for patients with ILD further impedes achievement of optimal clinical outcomes, including improved quality of life.
In this recorded webcast, case-based CME Outfitters activity, a panel of experts in ILD explores strategies for implementing equitable, multidisciplinary care for all patients with ILD. The critical roles of assessing social determinants of health, engaging in shared decision-making with patients, and evaluating potential implicit bias are among the topics covered in this important initiative.
Supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
Internists, primary care clinicians, pulmonologists, radiologists, infectious disease specialists, pathologists, nurse practitioners (NPs), physician associates (PAs), pharmacists, and other health care practitioners (HCPs) involved in the care and coordination of diverse populations of patients with ILD.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process.
Dr. Mageto reports the following financial relationships:
Advisory Board: Tvardi Therapeutics (Steering Committee)
Speakers Bureau: Boehringer Ingelheim Pharmaceuticals, Inc. Other financial or material Support: United Therapeutics Corporation (DSBM)
Dr. Adegunsoye reports the following financial relationships:
Advisory Board: AbbVie inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Genentech, Inc.; Inogen, Inc.; and patientMpower.
Consultant: Boehringer Ingelheim Pharmaceuticals, Inc. and Medscape.
Grants: CHEST Foundation; National Institutes of Health (NIH); and Pulmonary Fibrosis Foundation.
Speakers Bureau: Boehringer Ingelheim Pharmaceuticals, Inc.
Dr. Martinez reports the following financial relationships:
Advisory Board: Boehringer Ingelheim Pharmaceuticals, Inc.; Devpro Biopharma and GSK.
Consultant: AstraZeneca; Excalibur Pharmaceuticals; Lung Therapeutics; and Sanofi.
Research Support: ILD related SC for studies supported by Biogen; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; DevPro Biopharma; Nitto Denko Corporation; and Roche.
Disclosures were obtained from the CME Outfitters, LLC staff; no disclosures to report:
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Call us at 877.CME.PROS (877.263.7767).